Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Market Analysts Maintain Bullish Outlook on Terex Despite Recent Share Price Dip

Dieter Jaworski by Dieter Jaworski
September 2, 2025
in Analysis, Earnings, Industrial
0
Terex Stock
0
SHARES
257
VIEWS
Share on FacebookShare on Twitter

Terex Corporation delivered a robust second-quarter 2025 performance, surpassing analyst projections and reaffirming its full-year guidance. This strong operational showing presents a curious contrast to the recent softness observed in the company’s share price.

Exceeding Expectations Amid Market Challenges

The machinery manufacturer reported impressive financial results for the quarter. Revenue climbed to $1.49 billion, significantly exceeding the $1.46 billion forecast and representing a substantial 7.6% increase compared to the same period last year. On the earnings front, Terex posted adjusted earnings per share of $1.49, beating analyst estimates by $0.05.

A key driver of this outperformance was the company’s strategic focus on diversification. The Environmental Solutions Group (ESG), acquired in October 2024, delivered exceptional results that completely offset softer performance in the Aerials business segment. This acquisition is increasingly demonstrating its value as a strategic growth engine for the corporation.

Financial Community Expresses Confidence

Market experts have responded positively to these results. Investment firm Goldman Sachs upgraded its rating on Terex shares from “Neutral” to “Buy” back in May. More recently, UBS Group raised its price target to $52, while Evercore ISI maintains an even more optimistic outlook with a $62 target. The consensus price target among analysts stands at $51.44, suggesting significant potential upside from current trading levels.

Should investors sell immediately? Or is it worth buying Terex?

The recent 4.2% price correction to $49.94 (as of August 29) appears to represent a temporary consolidation phase following strong quarterly results rather than a fundamental concern. When viewed over a one-month horizon, the stock has declined just 1%, and it actually gained 2% over the past week.

Shareholder Returns and Forward Guidance

Management has demonstrated confidence in the company’s financial health through concrete actions. Terex has authorized a new $150 million share repurchase program while maintaining its dividend distribution for the fifth consecutive year. Shareholders will receive a quarterly dividend payment of $0.17 per share.

The leadership team has reaffirmed its full-year outlook, expecting adjusted earnings per share in the range of $4.70 to $5.10 on revenue between $5.3 billion and $5.5 billion. This maintained guidance during uncertain market conditions underscores the company’s operational resilience and stable financial footing.

Market observers now await the third-quarter results scheduled for release in late October, which will indicate whether the recent price adjustment presented a buying opportunity for investors.

Ad

Terex Stock: Buy or Sell?! New Terex Analysis from February 8 delivers the answer:

The latest Terex figures speak for themselves: Urgent action needed for Terex investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Terex: Buy or sell? Read more here...

Tags: Terex
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

February 8, 2026
DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Next Post
MYR Stock

MYR Shares Post Record Results Despite Recent Pullback

PennantPark Floating Rate Capital Stock

PennantPark Maintains Dividend Payout Despite Quarterly Earnings Shortfall

Clene Stock

A Pivotal Year for Clene's Neurological Treatment Pipeline

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com